Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma.
View/ Open
Date
2017-09Author
Kühnl, A
Cunningham, D
Chau, I
Type
Journal Article
Metadata
Show full item recordAbstract
After decades of intense research on genetic alterations in cancer and successful implementation of genetically-based targeted therapies, the field of cancer epigenetics is only beginning to be fully recognized. The discovery of frequent mutations in genes modifying the epigenome in diffuse large B-cell lymphoma (DLBCL) has highlighted the outstanding role of epigenetic deregulation in this disease. Identification of epigenetically-driven DLBCL subgroups and development of novel epigenetic drugs have rapidly advanced. However, further insights are needed into the biological consequences of epigenetic alterations and the possibility of restoring the aberrant epigenome with specific therapies to bring this treatment concept further into clinical practice. This review will summarize the main epigenetic changes found in DLBCL and their potential for precision medicine approaches.
Collections
Subject
Humans
Genetic Predisposition to Disease
Treatment Outcome
Genomics
Epigenesis, Genetic
Forecasting
Female
Male
Lymphoma, Large B-Cell, Diffuse
Molecular Targeted Therapy
Genetic Therapy
Precision Medicine
Research team
Medicine (RMH Smith Cunningham)
Language
eng
Date accepted
2017-07-31
License start date
2017-09
Citation
Cancer treatment reviews, 2017, 59 pp. 132 - 137